Product image of Kardegic (D,l-Lysine Acetylsalicylate) supplied by GNH India

Kardegic

Active Ingredient:
D,l-Lysine Acetylsalicylate
Origin:
EU

Kardegic (D,l-Lysine Acetylsalicylate)

D,l-Lysine Acetylsalicylate, the active ingredient in Kardegic, is a nonsteroidal anti-inflammatory drug presented as an oral tablet for oral use. It is employed to reduce platelet aggregation and to help prevent arterial clot formation in patients at risk of cardiovascular events.

GNH India supplies Kardegic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sanofi Winthrop Industrie

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Kardegic is an antiplatelet agent used in several cardiovascular and cerebrovascular conditions.

  • Prevention of arterial thrombosis: lowers the risk of clot formation in arteries.
  • Secondary prevention after myocardial infarction: reduces recurrence of heart attacks.
  • Stroke prevention: diminishes the chance of ischemic stroke in high‑risk patients.
  • Management of acute coronary syndrome: supports early treatment to limit platelet‑driven occlusion.

How It Works

  • Lysine acetylsalicylate irreversibly inhibits cyclooxygenase‑1 (COX‑1) in platelets, blocking the conversion of arachidonic acid to thromboxane A2. The resulting decrease in thromboxane A2 production impairs platelet aggregation, providing sustained antiplatelet activity that helps prevent arterial thrombus formation.

Side Effects

Adverse reactions may occur with any antiplatelet therapy.

Common Side Effects

  • Dyspepsia or stomach discomfort: mild gastrointestinal irritation.
  • Nausea: occasional feeling of queasiness.
  • Abdominal pain: transient cramping.
  • Increased minor bleeding: easy bruising or prolonged bleeding from cuts.

Serious or Rare Side Effects

  • Gastrointestinal ulcer or bleeding: severe hemorrhage requiring medical attention.
  • Hemorrhagic stroke: intracranial bleeding with neurological deficits.
  • Allergic reactions: rash, angioedema, or anaphylaxis.
  • Severe asthma exacerbation: bronchospasm in aspirin‑sensitive individuals.
  • Renal impairment: reduced kidney function in susceptible patients.

Precautions & Warnings

Before initiating therapy, consider the following safety measures.

  • Assess bleeding risk: review history of ulcers, surgery, or anticoagulant use.
  • Avoid in active peptic ulcer disease: contraindicated due to ulcer aggravation.
  • Monitor renal function: adjust use if significant impairment is present.
  • Use caution in asthma: may trigger bronchospasm in aspirin‑sensitive patients.
  • Store at ambient temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Kardegic can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Anticoagulants (e.g., warfarin): heightened bleeding risk.
  • Other NSAIDs: additive gastrointestinal toxicity.
  • Corticosteroids: increased ulceration potential.
  • Selective serotonin reuptake inhibitors (SSRIs): amplified bleeding tendency.
  • Alcohol: synergistic effect on gastric mucosa and bleeding.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: possible reduction in antihypertensive effect.

  • Diuretics: may affect renal clearance.
  • Lithium: increased lithium levels.
  • Methotrexate: reduced renal elimination, risk of toxicity.
  • Oral hypoglycemics: potential enhancement of hypoglycemic effect.

Frequently Asked Questions

Kardegic contains lysine acetylsalicylate, an antiplatelet agent used to prevent arterial thrombosis, support secondary prevention after myocardial infarction, reduce the risk of ischemic stroke, and aid in the management of acute coronary syndrome.

The compound irreversibly blocks cyclooxygenase‑1 (COX‑1) in platelets, preventing the formation of thromboxane A2, a potent promoter of platelet aggregation. This inhibition provides lasting antiplatelet activity that helps keep arterial blood flow unobstructed.

The specific dose of Kardegic is determined by the prescribing clinician based on the patient’s medical condition, risk factors, and concurrent therapies. Healthcare professionals tailor the regimen to achieve optimal antiplatelet effect while minimizing risk.

Safety of lysine acetylsalicylate in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the Kardegic product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kardegic’s active ingredient, lysine acetylsalicylate, is a salt form of aspirin that offers similar antiplatelet activity but may provide improved gastrointestinal tolerability for some patients. Both act by COX‑1 inhibition, yet formulation differences can affect absorption and side‑effect profiles.

Store Kardegic at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Kardegic is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed unless directed otherwise by a healthcare professional.

Serious risks include gastrointestinal ulceration or bleeding, hemorrhagic stroke, severe allergic reactions such as anaphylaxis, and bronchospasm in aspirin‑sensitive asthma patients. Prompt medical attention is required if any of these events occur.

Kardegic should be avoided in individuals with active peptic ulcer disease, known hypersensitivity to salicylates, severe uncontrolled asthma triggered by aspirin, or those currently experiencing significant bleeding. Consultation with a healthcare provider is essential before starting therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing D,l-Lysine Acetylsalicylate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT